Aimei Health Technology Co., Ltd

NASDAQ:AFJK

Shell Companies

Financial Services
$11.96 -10.76%

-$3.66 today

Market cap
$73.22M
Beta
0.23
P/E (TTM)
34.3
EPS (TTM)
$0.88
52W Low $6.75High $130.37

Volume 0.13M

Average 0.02M

AFJK Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Aimei Health Technology Co., LtdNASDAQ: AFJK

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $0.

Context

  • Cost of revenue increased in 0 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How AFJK compares with its peers on the latest reported figures

  • AFJK's LTM Mar 2026 cost of revenue of $0 is the 3rd highest of the 8 companies compared; the peer median is $0.
AFJK Competitors Peer median
Cost of Revenue for AFJK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CPBICentral Plains Bancshares, Inc. Common StockLTM Dec 2025$8.9M +11.2%+105.8%30.0%
UYSCUY Scuti Acquisition Corp.LTM Dec 2025$234.45K ———
AFJKAimei Health Technology Co., LtdLTM Mar 2026$0 ———
KOYNCSLM Digital Asset Acquisition Corp III Class A Ordinary SharesLTM Mar 2026$0 ———
EURKEureka Acquisition Corp Class A Ordinary ShareLTM Mar 2026$0 ———
BAYABayview Acquisition Corp Class A Ordinary SharesLTM Mar 2026$0 ———
ORIQUOrigin Investment Corp I UnitsLTM Mar 2026$0 ———
RIBBRibbon Acquisition CorpLTM Mar 2026$0 ———
Peer median (excluding AFJK) $0+11.2%+105.8%30.0%

Competitors are the stored peer set for AFJK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000
Cost of Revenue000
Gross Profit000
Gross Margin———
Research & Development000
Selling, General & Admin28.46K0835.76K
Operating Expenses28.46K1.07M835.76K
Depreciation & Amortization000
EBITDA171.39K(1.07M)(835.76K)
EBITDA Margin———
Operating Income(28.46K)(1.07M)(835.76K)
Operating Margin———
Interest Income199.85K3.62M1.9M
Interest Expense000
Other Income / Expenses199.85K3.62M1.9M
Income Before Tax171.39K2.55M1.06M
Pre-Tax Margin———
Income Tax Expense000
Net Income171.39K2.55M1.06M
Net Margin———
EPS (Basic)0.020.280.17
EPS (Diluted)0.020.280.17
Weighted Avg Shares9.03M9.03M4.05M
Weighted Avg Shares (Diluted)9.03M9.03M4.05M

Aimei Health Technology Co., Ltd

NASDAQ:AFJK

Intrinsic Alpha fair value

Locked

Current Price

$11.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.